| Literature DB >> 24335682 |
James L Mohler1, Philip W Kantoff, Andrew J Armstrong, Robert R Bahnson, Michael Cohen, Anthony Victor D'Amico, James A Eastham, Charles A Enke, Thomas A Farrington, Celestia S Higano, Eric Mark Horwitz, Mark H Kawachi, Michael Kuettel, Richard J Lee, Gary R Macvicar, Arnold W Malcolm, David Miller, Elizabeth R Plimack, Julio M Pow-Sang, Sylvia Richey, Mack Roach, Eric Rohren, Stan Rosenfeld, Eric J Small, Sandy Srinivas, Cy Stein, Seth A Strope, Jonathan Tward, Patrick C Walsh, Dorothy A Shead, Maria Ho.
Abstract
The NCCN Guidelines for Prostate Cancer provide multidisciplinary recommendations on the clinical management of patients with prostate cancer. This report highlights notable recent updates. Radium-223 dichloride is a first-in-class radiopharmaceutical that recently received approval for the treatment of patients with symptomatic bone metastases and no known visceral disease. It received a category 1 recommendation as both a first-line and second-line option. The NCCN Prostate Cancer Panel also revised recommendations on the choice of intermittent or continuous androgen deprivation therapy based on recent phase III clinical data comparing the 2 strategies in the nonmetastatic and metastatic settings.Entities:
Mesh：
Substances：
Year: 2013 PMID： 24335682 DOI： 10.6004/jnccn.2013.0174
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908